Free Trial
NASDAQ:ARGX

argenx (ARGX) Stock Price, News & Analysis

argenx logo
$649.67 +9.77 (+1.53%)
Closing price 05/2/2025 04:00 PM Eastern
Extended Trading
$653.00 +3.33 (+0.51%)
As of 05/2/2025 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About argenx Stock (NASDAQ:ARGX)

Key Stats

Today's Range
$646.58
$656.29
50-Day Range
$546.22
$649.67
52-Week Range
$352.77
$678.21
Volume
318,117 shs
Average Volume
309,140 shs
Market Capitalization
$39.67 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$699.28
Consensus Rating
Moderate Buy

Company Overview

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

argenx Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
51st Percentile Overall Score

ARGX MarketRank™: 

argenx scored higher than 51% of companies evaluated by MarketBeat, and ranked 207th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    argenx has received a consensus rating of Moderate Buy. The company's average rating score is 2.91, and is based on 19 buy ratings, 3 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    argenx has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about argenx's stock forecast and price target.
  • Earnings Growth

    Earnings for argenx are expected to grow by 246.65% in the coming year, from $3.13 to $10.85 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of argenx is -738.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of argenx is -738.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    argenx has a P/B Ratio of 9.39. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about argenx's valuation and earnings.
  • Percentage of Shares Shorted

    3.83% of the float of argenx has been sold short.
  • Short Interest Ratio / Days to Cover

    argenx has a short interest ratio ("days to cover") of 6.8.
  • Change versus previous month

    Short interest in argenx has recently increased by 5.58%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    argenx does not currently pay a dividend.

  • Dividend Growth

    argenx does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    3.83% of the float of argenx has been sold short.
  • Short Interest Ratio / Days to Cover

    argenx has a short interest ratio ("days to cover") of 6.8.
  • Change versus previous month

    Short interest in argenx has recently increased by 5.58%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    argenx has a news sentiment score of 1.14. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.83 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 18 news articles for argenx this week, compared to 10 articles on an average week.
  • Search Interest

    6 people have searched for ARGX on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • MarketBeat Follows

    10 people have added argenx to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, argenx insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 2.43% of the stock of argenx is held by insiders.

  • Percentage Held by Institutions

    60.32% of the stock of argenx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about argenx's insider trading history.
Receive ARGX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for argenx and its competitors with MarketBeat's FREE daily newsletter.

ARGX Stock News Headlines

Virtually Limitless Energy?
A radical energy breakthrough could change everything. Scientists at MIT and a stealth startup may have discovered a new form of power—what some are calling “Helios” technology. It’s not solar, wind, or even nuclear fission. In fact, it could yield more energy than oil, gas, and coal combined—without harmful byproducts. This obscure company could be at the center of the next trillion-dollar energy revolution.
Argenx Stock Extends Rally In A Base As Earnings Loom
See More Headlines

ARGX Stock Analysis - Frequently Asked Questions

argenx's stock was trading at $615.00 at the beginning of 2025. Since then, ARGX shares have increased by 5.6% and is now trading at $649.67.
View the best growth stocks for 2025 here
.

argenx SE (NASDAQ:ARGX) announced its earnings results on Thursday, February, 27th. The company reported $1.58 earnings per share for the quarter, topping analysts' consensus estimates of $0.98 by $0.60. The company had revenue of $761.22 million for the quarter, compared to the consensus estimate of $678.52 million. argenx had a negative net margin of 2.11% and a negative trailing twelve-month return on equity of 1.45%.
Read the conference call transcript
.

argenx (ARGX) raised $65 million in an IPO on Thursday, May 18th 2017. The company issued 3,600,000 shares at a price of $18.18 per share. Cowen and Company and Piper Jaffray acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

argenx's top institutional shareholders include Allspring Global Investments Holdings LLC (0.29%), GAMMA Investing LLC (0.22%), TimesSquare Capital Management LLC (0.21%) and Perpetual Ltd (0.19%).

Shares of ARGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that argenx investors own include Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), Broadcom (AVGO), Taiwan Semiconductor Manufacturing (TSM), CrowdStrike (CRWD) and Adobe (ADBE).

Company Calendar

Last Earnings
2/27/2025
Today
5/02/2025
Next Earnings (Estimated)
5/08/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ARGX
Fax
N/A
Employees
650
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$699.28
High Stock Price Target
$1,100.00
Low Stock Price Target
$500.00
Potential Upside/Downside
+7.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.91
Research Coverage
23 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
207.56
P/E Growth
N/A
Net Income
$-295,050,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$2.19 billion
Price / Cash Flow
N/A
Book Value
$69.22 per share
Price / Book
9.39

Miscellaneous

Free Float
59,285,000
Market Cap
$39.67 billion
Optionable
Optionable
Beta
0.60
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.

Get This Free Report

This page (NASDAQ:ARGX) was last updated on 5/3/2025 by MarketBeat.com Staff
From Our Partners